Tarsus Pharmaceuticals (TARS) files Section 144 notice to sell 12,500 shares

Rhea-AI Filing Summary

Tarsus Pharmaceuticals filed a Section 144 notice regarding the sale of 12,500 shares of Common Stock. The notice lists the sale filing on 03/16/2026 and records prior sales on 12/15/2025 by related holders with reported dollar amounts. The filing references a 01/10/2017 stock option exercise for 12,500 shares.

Insights

Equity Transactions Analyst

Routine Section 144 sale notice for 12,500 common shares; prior related disposals shown.

The excerpt lists a proposed sale of 12,500 shares with the filing dated 03/16/2026 and records prior dispositions on 12/15/2025 by two related entities showing 12,500 and 10,446 shares with corresponding dollar amounts. The entry notes these shares originated from a 01/10/2017 stock option exercise.

Cash‑flow treatment and whether sales are planned as block trades, open‑market or other methods are not stated in the provided excerpt; subsequent filings or broker disclosures would specify execution method and timing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	MERRILL LYNCH 520 NEWPORT CENTER DRIVE 20TH FLOOR NEWPORT BEACH CA 92660	12500	859787.14	42557492	03/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	01/10/2017	STOCK OPTION EXERCISE	TARSUS PHARMACEUTICALS INC			12500	01/10/2017	CASH

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
WILLIAM J LINK 15440 LAGUNA CANYON ROAD SUITE 160 IRVINE CA 92618	COMMON	12/15/2025	12500	1017799.74
LINK FAMILY ENTERPRISE LP 15440 LAGUNA CANYON ROAD SUITE 160 IRVINE CA 92618	COMMON	12/15/2025	10446	846862.01

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the TARS Section 144 notice cover?

It covers the proposed sale of 12,500 shares of Common Stock. The filing is dated 03/16/2026 and references prior related sales on 12/15/2025 with reported dollar amounts.

Who sold shares in the past three months according to the filing?

Two related holders reported sales on 12/15/2025. The excerpt lists one entry of 12,500 shares and another of 10,446 shares with corresponding dollar values in the filing.

What is the origin of the shares referenced in the notice?

The filing references a stock option exercise on 01/10/2017 for 12,500 shares. That exercise date is recorded in the securities history shown in the excerpt.

Does the filing state how sales will be executed or who receives proceeds?

The excerpt does not specify execution methods or proceeds recipients. The provided content lists share counts, dates, and dollar amounts but does not describe trading methods or cash‑flow treatment.